Unravelling the Molecular Identification and Antifungal Susceptibility Profiles of Aspergillus spp. Isolated from Chronic Pulmonary Aspergillosis Patients in Jakarta, Indonesia: The Emergence of Cryptic Species

Cryptic species of have rapidly increased in the last few decades. Chronic pulmonary aspergillosis (CPA) is a debilitating fungal infection frequently affecting patients with previous TB. The identification and antifungal susceptibility profiles of different species of are important to support the m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of fungi (Basel) 2022-04, Vol.8 (4), p.411
Hauptverfasser: Rozaliyani, Anna, Abdullah, Asriyani, Setianingrum, Findra, Sjamsuridzal, Wellyzar, Wahyuningsih, Retno, Bowolaksono, Anom, Fatril, Ayu Eka, Adawiyah, Robiatul, Tugiran, Mulyati, Syam, Ridhawati, Wibowo, Heri, Kosmidis, Chris, Denning, David W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Cryptic species of have rapidly increased in the last few decades. Chronic pulmonary aspergillosis (CPA) is a debilitating fungal infection frequently affecting patients with previous TB. The identification and antifungal susceptibility profiles of different species of are important to support the management of CPA. The aim of this study was to describe the molecular and susceptibility profiles of isolated from CPA patients. The species identity of isolates was determined by combined DNA analyses of internal transcribed space (ITS), partial β-tubulin genes, and part of the calmodulin gene. We revealed a high (27%) prevalence of cryptic species among previous tuberculosis patients with persistent symptoms. Twenty-nine (49%) patients met the criteria for diagnosis of CPA with 24% containing cryptic species. This is the first report of five cryptic species from clinical isolates in Indonesia: , , , and . Significantly, there was decreased sensitivity against itraconazole in the CPA group (66% susceptible to itraconazole) compared to the non-CPA group (90% susceptible to itraconazole) ( = 0.003). The species-level characterisation of and its antifungal susceptibility tests demands greater attention to better the management of CPA patients.
ISSN:2309-608X
2309-608X
DOI:10.3390/jof8040411